Turk Ilac ve Serum Sanayi AS - Asset Resilience Ratio
Turk Ilac ve Serum Sanayi AS (TRILC) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TRILC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2022)
This chart shows how Turk Ilac ve Serum Sanayi AS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Turk Ilac ve Serum Sanayi AS (TRILC) total assets.
Liquid Assets Composition Over Time
This chart breaks down Turk Ilac ve Serum Sanayi AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Turk Ilac ve Serum Sanayi AS (TRILC) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0% |
| Short-term Investments | TL19.65K | 0.0% |
| Total Liquid Assets | TL19.65K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Turk Ilac ve Serum Sanayi AS maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Turk Ilac ve Serum Sanayi AS Industry Peers by Asset Resilience Ratio
Compare Turk Ilac ve Serum Sanayi AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Turk Ilac ve Serum Sanayi AS (2022–2022)
The table below shows the annual Asset Resilience Ratio data for Turk Ilac ve Serum Sanayi AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | TL19.65K ≈ $440.11 |
TL1.04 Billion ≈ $23.39 Million |
-- |
About Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. Turk Ilac Ve Serum Sanayi Anonim Sirketi was founded in 2010 and is headquartered in Anka… Read more